LabCorp. has acquired Sciformix Corporation. Sciformix will become part of Covance, LabCorp's drug development business.
This acquisition strengthens our position in the later phases of drug and device development, particularly for post-marketing pharmacovigilance and market access solutions, said David P. King, chairman and chief executive officer of LabCorp. The addition of Sciformix's scientific and technology expertise, combined with its quality-driven processes, will support Covance's work in transforming drug development through innovation and greater efficiency.
Sciformix's offerings include post-marketing safety and risk management, clinical development support services, regulatory affairs and operations, technology services, and real-world evidence solutions. The majority of Sciformix's 1,100 employees are based in Asia, accelerating Covance's global expansion.
The development process does not end once a drug or device is approved, said Bill Hanlon, Ph.D., group president of Clinical Development and Commercialization Services at Covance. More than ever, approved treatments must be monitored closely to demonstrate a continued favorable benefit-risk ratio in a much broader population and to safeguard patient safety. Pharmacovigilance solutions address that need. Sciformix's services and expertise are a compelling addition to Covance's portfolio. With its scientific knowledge and high-quality delivery, Sciformix is a great fit with our...